Satellos Bioscience Inc. (NASDAQ:MSLE) Receives $18.00 Average Target Price from Analysts

Shares of Satellos Bioscience Inc. (NASDAQ:MSLE) have been assigned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $18.00.

MSLE has been the topic of a number of recent research reports. Guggenheim started coverage on shares of Satellos Bioscience in a research note on Tuesday, April 28th. They set a “buy” rating and a $23.00 price target on the stock. Wall Street Zen upgraded Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Canaccord Genuity Group raised shares of Satellos Bioscience to a “moderate buy” rating in a research note on Thursday, May 21st. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Satellos Bioscience in a research note on Monday, May 18th. Finally, Cantor Fitzgerald assumed coverage on shares of Satellos Bioscience in a research note on Wednesday, March 11th. They set an “overweight” rating on the stock.

Satellos Bioscience Trading Down 0.9%

NASDAQ:MSLE opened at $5.62 on Friday. The firm has a market cap of $117.06 million, a PE ratio of -3.51 and a beta of 1.54. Satellos Bioscience has a one year low of $4.56 and a one year high of $13.39. The firm’s fifty day moving average is $6.87.

Satellos Bioscience (NASDAQ:MSLE) last released its earnings results on Friday, May 15th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.02). On average, research analysts forecast that Satellos Bioscience will post -1.69 EPS for the current fiscal year.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.